Home » Stocks » NVO

Novo Nordisk A/S (NVO)

Stock Price: $67.81 USD 0.60 (0.89%)
Updated December 4, 4:00 PM EST - Market closed

NVO Stock Price Chart

Key Info

Market Cap 155.47B
Revenue (ttm) 19.54B
Net Income (ttm) 6.72B
Shares Out 2.36B
EPS (ttm) 2.46
PE Ratio 27.54
Forward PE 21.69
Dividend $1.04
Dividend Yield 1.53%

Stock Quote

Trading Day December 4
Last Price $67.81
Previous Close $67.21
Change ($) 0.60
Change (%) 0.89%
Day's Open 67.75
Day's Range 67.64 - 68.23
Day's Volume 562,458
52-Week Range 49.46 - 73.62

NVO Stock News

GlobeNewsWire - 23 hours ago

Bagsværd, Denmark, 4 December 2020 – Novo Nordisk today announced the submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for subcutaneous semaglutide 2.4 m...

InvestorPlace - 1 day ago

These 7 cheap stocks span industry and have a great chance to appreciate in price next year. Click here for the metrics and reasoning.

Other stocks mentioned: AAN, AFL, CVS, HUM, IBM, INTC
Business Wire - 1 day ago

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Emispher...

Seeking Alpha - 4 days ago

Novo Nordisk A/S (NVO) CEO Lars Jørgensen on ESG Conference Call - Transcript

GlobeNewsWire - 4 days ago

Novo Nordisk A/S – Share repurchase programme

Zacks Investment Research - 1 week ago

Let's see if Novo Nordisk A/S (NVO) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

GlobeNewsWire - 1 week ago

Bagsværd, Denmark, 23 November 2020 – On 3 November 2020, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament ...

Zacks Investment Research - 2 weeks ago

Novo Nordisk's (NVO) semaglutide 2.0 mg demonstrates superior reduction in HbA1c versus once-weekly semaglutide 1.0 mg in people with type II diabetes.

Zacks Investment Research - 2 weeks ago

Gilead (GILD) and Novo Nordisk present favorable outcomes from a mid-stage study in NASH patients.

Other stocks mentioned: GILD
GuruFocus - 3 weeks ago

Danish pharmaceutical giant Novo Nordisk AS (NYSE:NVO) hopes to apply a unique drug delivery technology it acquired to enable people to take more of its drugs by mouth.

Investors Business Daily - 4 weeks ago

Novo Nordisk, trading near record highs, early Friday announced it would buy a maker of proprietary oral drug delivery technology, a longtime partner, for $1.8 billion, and NVO stock rose. The...

GlobeNewsWire - 4 weeks ago

Bagsværd , Denmark, 6 November 202 0 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated person...

GlobeNewsWire - 4 weeks ago

ROSELAND, N.J., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (“Emisphere” or the “Company”) today announced that it has entered into a definitive agreement with Novo Nordisk ...

Reuters - 4 weeks ago

Danish diabetes drug maker Novo Nordisk will acquire U.S. Emisphere Technologies, which specialises in developing orally administered versions of drugs, in a deal totalling $1.8 billion, it sa...

Zacks Investment Research - 4 weeks ago

Novo Nordisk (NVO) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

GlobeNewsWire - 1 month ago

Bagsværd, Denmark, 4 November 2020 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons ...

GlobeNewsWire - 1 month ago

Novo Nordisk A/S purchases B shares worth DKK 2,913 million from Novo Holdings A/S under the 2020 share repurchase programme

Seeking Alpha - 1 month ago

Novo Nordisk A/S (NVO) CEO Lars Fruergaard Jorgensen on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 1 month ago

Novo Nordisk (NVO) misses earnings and sales estimates in the third quarter of 2020.

Invezz - 1 month ago

Novo Nordisk (ETR: NOVC) said on Friday that its net profit in the fiscal third quarter came in better than expected. The company highlighted that patients in Europe and the United States stoc...

GlobeNewsWire - 1 month ago

30 October 2020 - Financial report for the period 1 January 2020 to 30 September 2020

GuruFocus - 1 month ago

In light of coronavirus cases increasing both domestically and internationally, four health care companies with strong business quality are Biogen Inc. (NASDAQ:BIIB), Novo Nordisk A/S (NYSE:NV...

Other stocks mentioned: BIIB, ILMN, RMD
Zacks Investment Research - 1 month ago

SNY vs. NVO: Which Stock Is the Better Value Option?

Other stocks mentioned: SNY
Kiplinger - 1 month ago

Leading wealth managers including BlackRock, Merrill Lynch and Putnam are advising their clients to invest in foreign stocks to take advantage of better values overseas. And the market's best ...

Other stocks mentioned: BTI, NSRGY, NVS, RHHBY, SAP, SNY, UL, UN, VEA
Zacks Investment Research - 1 month ago

Novo Nordisk (NVO) raises 2020 sales and operating profit outlook at constant exchange rates.

GlobeNewsWire - 1 month ago

Bagsværd, Denmark, 8 October 2020 – Novo Nordisk today announced that the full-year sales and operating profit outlook at constant exchange rates (CER) has been raised.                    

Seeking Alpha - 2 months ago

With sales growing 8% and net profits growing 12% in the first half of 2020, Novo Nordisk could report solid numbers.

InvestorPlace - 2 months ago

The company's value chain may have been shaken by Covid-19 but it wasn't broken, so Novo Nordisk stock holders should stay invested. The post Hold Novo Nordisk Shares for Consistent Internatio...

GuruFocus - 2 months ago

As the world grapples with an unprecedented coronavirus pandemic, five health care stocks that have outperformed the Standard & Poor's 500 Index by at least 5% in the year to date are Amerisou...

Other stocks mentioned: ABC, CHE, NEOG, RMD
Zacks Investment Research - 2 months ago

SNY vs. NVO: Which Stock Is the Better Value Option?

Other stocks mentioned: SNY
PRNewsWire - 2 months ago

WASHINGTON, Sept. 10, 2020 /PRNewswire/ -- The American College of Cardiology, in partnership with Novo Nordisk Inc.

InvestorPlace - 2 months ago

The healthcare industry has historically delivered market-beating returns. And the current pandemic has created new opportunities in the sector.

Other stocks mentioned: AAPL, HCA, JNJ, SYK, TDOC, VTR
GuruFocus - 3 months ago

Other pharmas working on stem cells to repair degenerative brain damage

Other stocks mentioned: AZN
PRNewsWire - 3 months ago

SEATTLE, Aug. 24, 2020 /PRNewswire/ -- UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY In re NOVO NORDISK SECURITIES LITIGATION Master File No.

Investors Business Daily - 3 months ago

Novo Nordisk shows improving price performance, earning an upgrade to its IBD Relative Strength Rating The post Novo Nordisk Getting Closer To Key Technical Measure appeared first on Investor'...

The Dog of Wall Street - 3 months ago

The Danish multinational offers an exciting growth opportunity.

Seeking Alpha - 3 months ago

Novo Nordisk: Long-Term Growth By CV Risk Factor Reduction

Zacks Investment Research - 3 months ago

Novo Nordisk (NVO) resumes the phase III studies on concizumabin in hemophilia A and B patients regardless of inhibitor status.

The Motley Fool - 3 months ago

DexCom, Tandem Diabetes, and Novo Nordisk have plenty of momentum and growth ahead, making them excellent buys this month.

Other stocks mentioned: DXCM, TNDM
Seeking Alpha - 3 months ago

The biotech sector had a troubled Q2, as doctor visits were curtailed and new Rx'es were in short supply; R&D efforts were also harmed.

Other stocks mentioned: AZN, GILD, IBB, JNJ, LLY, MRK, MRNA, REGN, RHHBY, SNY, VRTX, XBI
Seeking Alpha - 3 months ago

Novo Nordisk A/S (NVO) CEO Lars Fruergaard Jorgensen on Q2 2020 Results - Earnings Call Transcript

CNBC International TV - 3 months ago

Novo Nordisk posts second-quarter profit rise, CEO 'optimistic' about weathering virus impacts

Lars Fruergaard Jørgensen, CEO of Novo Nordisk, discusses the company's half-year results and the impacts of the pandemic on the business.

Zacks Investment Research - 3 months ago

Novo Nordisk's (NVO) earnings surpass estimates but revenues miss the same in the second quarter of 2020.

Invezz - 3 months ago

Novo Nordisk (ETR: NOVC) said on Thursday that its net profit in the fiscal second quarter came in stronger than what the experts had forecast. The company said that destocking and fewer new p...

GlobeNewsWire - 3 months ago

Financial report for the period 1 January 2020 to 30 June 2020

GuruFocus - 4 months ago

Among the largest publicly traded pharmaceutical companies, Novo Nordisk (NYSE:NVO) and Roche (RHHBY) had the highest returns on invested capital during the period from 2011 to 2019, according...

Other stocks mentioned: RHHBY
CNBC International TV - 4 months ago

Lancet editor: Hope to have Covid-19 vaccine next year

Richard Horton, editor-in-chief of The Lancet, discusses the outlook for a Covid-19 vaccine.

Other stocks mentioned: AZN, BAYRY, GSK, NVS, RHHBY, SNY
InvestorPlace - 4 months ago

There’s a select group of pharmaceutical stocks that stand to win without even looking for a Covid-19 cure. The post The 7 Best Pharmaceutical Stocks That Go Beyond the Covid-19 Chase appeare...

Other stocks mentioned: ABBV, HZNP, LLY, RDY, UTHR, ZTS
Zacks Investment Research - 4 months ago

Shares of Novo Nordisk (NVO) rally on solid product portfolio aided by new approvals.

GuruFocus - 4 months ago

In light of Novavax Inc. (NASDAQ:NVAX) getting $1.6 billion in federal aid for its coronavirus vaccine candidate, investors might find opportunities in biotechnology stocks that have high fina...

Other stocks mentioned: ALXN, GLPG, REGN, VRTX

About NVO

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharmaceuticals. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company has a... [Read more...]

Industry
Biotechnology
Founded
1923
CEO
Lars Fruergaard Joergensen
Employees
44,326
Stock Exchange
NYSE
Ticker Symbol
NVO
Full Company Profile

Financial Performance

In 2019, NVO's revenue was 122.02 billion, an increase of 9.11% compared to the previous year's 111.83 billion. Earnings were 38.95 billion, an increase of 0.84%.

Financial numbers in millions DKK.
Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for NVO stock is "Buy." The 12-month stock price forecast is 75.06, which is an increase of 10.69% from the latest price.

Price Target
$75.06
(10.69% upside)
Analyst Consensus: Buy